Heart 2009;95:1153-1158
Original articles
Heart rhythm disorders and pacemakers
Troponin T elevation after implanted defibrillator discharge predicts survival
1 Cardiac Electrophysiology Service, Department of Medicine, Bridgeport Hospital, Yale University School of Medicine, Bridgeport, Connecticut, USA
2 Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA
Dr D Blendea, Cardiac Electrophysiology Service, Department of Medicine, Bridgeport Hospital, Yale University School of Medicine, 267 Grant St, Bridgeport, CT 06610, USA; dblendea{at}me.com
Background: Cardiac troponin T (cTnT) elevations have been reported to occur after implantable cardioverter-defibrillator (ICD) discharges, but their prognostic significance is unknown.
Objective: To evaluate whether cTnT elevations occurring after ICD discharges have an impact on survival.
Design: Prospective observational study.
Patients: 174 patients (mean (SD) age 68 (12) years, 32 women) who received spontaneous (n = 66) or induced (n = 108) ICD discharges were studied. The mean (SD) left ventricular ejection fraction was 29 (11)%.
Main outcome measures: Troponin T was measured between 12 and 24 h after ICD discharge. Patients received between 1 and 19 discharges (mean (SD) 2.4 (2.4)), with total delivered energy ranging from 6 to 288 J (mean (SD) 41 (63) J). The relationship between cTnT levels and all-cause mortality was assessed in univariate and multivariate analyses.
Results: During a median follow-up period of 41.8 months (range 3–123), 56 patients died. Patients with a post-discharge cTnT level of 
0.05 ng/ml had worse survival than those with cTnT <0.05 ng/ml. The significant relationship between raised cTnT and survival was retained in Cox multivariate analysis adjusted for total ICD energy delivered during an arrhythmia episode, age, sex, presence of coronary artery disease, left ventricular ejection fraction and serum creatinine.
Conclusions: Elevation of troponin T after ICD discharge, even when it occurs after device testing, is a risk factor for mortality that is independent of other common clinical factors that predict survival in such patients.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
-
All Versions of this Article:
hrt.2008.162677v1
95/14/1153 most recent - Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
